Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Diagnosis
3.2. Snippet by Drug/Therapy
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research and Development
4.1.1.2. Rising Pipeline Drugs
4.1.2. Restraints
4.1.2.1. Lack of Drug Approvals
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Tetrabenazine*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Deutetrabenazine
7.4. Antipsychotic drugs
7.4.1.1. Clonazepam (Klonopin)
7.4.1.2. Haloperidol
7.4.1.3. Clozapine
7.4.1.4. Others
7.5. Psychotropic medication
7.5.1.1. Fluoxetine (Prozac)
7.5.1.2. Sertraline (Zoloft)
7.5.1.3. Citalopram (Celexa)
7.5.1.4. Others
7.6. Antidopaminergics
7.6.1.1. Metoclopramide
7.6.1.2. Droperidol
7.6.1.3. Haloperidol
7.6.1.4. Chlorpromazine
7.6.1.5. Others
7.7. Antidepressants
7.7.1.1. Citalopram
7.7.1.2. Escitalopram
7.7.1.3. Sertraline
7.7.1.4. Others
7.8. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Teva Pharmaceutical Industries Ltd.
11.1.1. Company Overview
11.1.2. Diagnosis Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Apotex Corporation
11.3. Pfizer, Inc.
11.4. Rosemont Pharma
11.5. Agnito Pharma
11.6. Merck & Co, Inc.
11.7. Eli Lilly and Company
11.8. Ralington Pharma
11.9. Par Pharmaceutical
11.10. Accord Healthcare
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us